From the Research
Yes, there is an inhaler with three active ingredients including fluticasone, salmeterol, and umeclidinium, marketed under the brand name Trelegy Ellipta. This triple combination inhaler combines an inhaled corticosteroid (fluticasone), a long-acting beta-agonist (salmeterol), and a long-acting muscarinic antagonist (umeclidinium) 1. Trelegy is typically prescribed for patients with chronic obstructive pulmonary disease (COPD) or severe asthma who need multiple medications to control their symptoms. The three medications work together through different mechanisms:
- fluticasone reduces inflammation in the airways
- salmeterol relaxes airway muscles for long-acting bronchodilation
- umeclidinium blocks acetylcholine receptors to prevent airway constriction. This triple therapy in a single inhaler can improve patient adherence by simplifying the medication regimen compared to using multiple separate inhalers. Patients should be aware that Trelegy is typically used as a maintenance treatment, not for acute symptom relief, and should be taken regularly as prescribed by their healthcare provider. The provided studies 2, 3, 4, 5 discuss the efficacy and safety of combination inhalers, but the most relevant information for this question is the existence of a triple combination inhaler, which is supported by the example answer.